4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Free Cash Flow of -$68.1 million for Q1 2026, down 42.23% year-over-year from -$117.9 million in Q1 2025, and down 381.16% quarter-over-quarter from $24.2 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Free Cash Flow (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Free Cash Flow for 7 consecutive years, with -$68.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 42.23% year-over-year to -$68.1 million; the TTM figure through Mar 2026 stood at -$134.2 million (up 14.21% YoY), while the FY2025 annual figure was -$114.0 million, up 17.61% from the prior year.
- Free Cash Flow declined to -$68.1 million in Q1 2026 per FDMT's latest filing, from $24.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $24.2 million in Q4 2025 and bottomed at -$68.1 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$28.4 million across 5 years, with a median of -$29.8 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow plunged 911.65% — and 2025, when it surged 151.76%.
- 4D Molecular Therapeutics' Free Cash Flow stood at -$21.8 million in 2022, then fell by 4.08% to -$22.7 million in 2023, then slumped by 106.57% to -$46.8 million in 2024, then jumped by 151.76% to $24.2 million in 2025, then tumbled by 381.16% to -$68.1 million in 2026.
- Business Quant data shows FDMT's Free Cash Flow at -$68.1 million in Q1 2026, $24.2 million in Q4 2025, and -$46.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -69.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.98 Mn |
| Jun 30, 2026 | -69.98 Mn |
| Mar 31, 2026 | -68.13 Mn |
| Mar 31, 2026 | -68.13 Mn |
| Dec 31, 2025 | 24.23 Mn |
| Dec 31, 2025 | 24.23 Mn |
| Sep 30, 2025 | -46.41 Mn |
| Sep 30, 2025 | -46.41 Mn |
| Jun 30, 2025 | -43.93 Mn |
| Jun 30, 2025 | -43.93 Mn |
| Mar 31, 2025 | -47.90 Mn |
| Mar 31, 2025 | -47.90 Mn |
| Dec 31, 2024 | -46.81 Mn |
| Dec 31, 2024 | -46.81 Mn |
| Sep 30, 2024 | -31.17 Mn |
| Sep 30, 2024 | -31.17 Mn |
| Jun 30, 2024 | -30.59 Mn |
| Jun 30, 2024 | -30.59 Mn |
| Mar 31, 2024 | -29.80 Mn |
| Mar 31, 2024 | -29.80 Mn |